Share
Scientific Advice for Startups: Turning the Right Questions into Regulatory Clarity
Scientific Advice is one of the few moments in early development where a biotech can test its development assumptions with regulators before those assumptions become timelines, contracts, and irreversible design choices.
For lean teams, this interaction offers a critical opportunity to confirm what evidence regulators will expect, where the main risks lie, and which trade-offs may be acceptable. EMA frames Scientific Advice exactly in those terms: as a mechanism to help developers generate robust evidence on benefits and risks and support timely, sound development.
Scientific Advice is therefore not just a regulatory step. It is where the development strategy is tested in practice. When used well, it reduces rework before CTA preparation and helps teams avoid last-minute complications as they move into first-in-human.
In this blog post, we outline how startups can structure Scientific Advice around key development decisions so that regulatory feedback becomes directly actionable.
Start with Decisions, Not Questions
The value of Scientific Advice depends largely on how the request is framed. The strongest Scientific Advice packages are built around a small set of high-impact decisions your team must make as the development program moves forward. For early-stage biotechs, those decisions usually cluster into four areas:
Once the decisions are clear, questions become easier to write, and the advice becomes easier to use.
Structure Questions for Actionable Regulatory Advice
Many startups struggle to get value from Scientific Advice because their questions are framed too broadly or too generically. When questions are vague, regulators can only respond at a high level, which limits their practical usefulness.
EMA guidance makes it clear that Scientific Advice is intended to support concrete development decisions, not to validate an entire program. The most effective questions are therefore structured around real choices and clearly articulated risks. They describe the current proposal, explain why it has been selected, and highlight the uncertainties the team is trying to manage.
When questions are framed in this way, regulators can focus their feedback on evidence requirements, alternative approaches, and risk mitigation strategies. This turns Scientific Advice into a tool for decision-making rather than a general discussion.
Treat Scientific Advice as an Integrated Development Exercise
For emerging biotechs, Scientific Advice often loses value when it is approached in silos, with clinical questions prepared separately from CMC considerations, quality topics postponed, and safety strategy discussed in isolation. The result is a fragmented submission that does not fully reflect how the development plan actually functions.
A practical way to ensure consistency is to begin the document with a concise overview of the development strategy, outlining what the product is, which indication is targeted, what the next milestone will be, and where the main uncertainties sit. Each question should then link clearly to one of these uncertainties, making it easier for regulators to provide focused feedback and for the company to translate that feedback into concrete actions.
Use the process to your advantage
Scientific Advice is a defined procedure with preparatory steps, validation, assessment, and follow-up. EMA’s applicant guidance helps teams understand what to include and how to structure the request.
Two operational moves help lean teams avoid waste:
This avoids the common situation where advice arrives, the team agrees it is important, and then execution drifts because no one owns conversion.
How EMA SME Support Reduces the Barrier to Scientific Advice
EMA provides specific fee reductions and support mechanisms for companies that qualify as SMEs, with the explicit aim of encouraging earlier interaction with regulators. These incentives apply to Scientific Advice procedures and are designed to lower the financial barriers that often delay regulatory engagement in small organizations.
For many emerging biotechs, this significantly changes the cost-benefit balance. Scientific Advice becomes a viable investment earlier in development, at a point where regulatory input can still shape strategy, prevent unnecessary rework, and deliver the greatest long-term value.
Final Thoughts
Scientific Advice delivers the greatest value when it is used to accelerate critical development decisions, by clarifying priorities, reducing uncertainty, and aligning the overall program before significant resources are committed.
Its impact does not depend on the number of questions submitted, but on their relevance and precision, ensuring they are directly connected to real development choices and supported by a consistent strategy across clinical, CMC, quality, and safety domains.
Preparing for Scientific Advice?
Early regulatory interactions can significantly shape the trajectory of a development program. QbD Group supports emerging biotechs in preparing and structuring Scientific Advice requests, aligning clinical, CMC, and regulatory strategy to ensure that regulatory feedback translates into clear development decisions.
%20Checklist.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.png)